Evidence map›Paper›PMID 42146532›Full record

ArticlebioRxiv : the preprint server for biology2026

CpG island density predicts CBP/p300 dependency across 3D chromatin clusters.

Md Imdadul H Khan, Matthew S Chang, Yaw Asante, Maya K Al-Haddad, Teagan Kukhta, Bhavatharini Udhayakumar, Ana María Garzón-Porras, Elena-Loredana Rotariu, Saanvi Aneja, Jordyn L Kelly and 9 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Md Imdadul H KhanDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0001-8002-5600
Matthew S ChangDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Yaw AsanteDepartment of Nutrition, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Maya K Al-HaddadDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Teagan KukhtaDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Bhavatharini UdhayakumarDepartment of Nutrition, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Ana María Garzón-PorrasDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Elena-Loredana RotariuDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Saanvi AnejaDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Jordyn L KellyDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Carrietta B Farma-HaiDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Kavi UllalDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Diana H ChinDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Alexander J FederationTalus Bioscience, Inc., Seattle, WA, USA.
Lindsay K PinoTalus Bioscience, Inc., Seattle, WA, USA.
Julia RobbinsTalus Bioscience, Inc., Seattle, WA, USA.
Marco WachtelBalgrist University Hospital, Lengghalde 5, CH-8008, Zürich, Switzerland.
Shaun R StaufferCenter for Therapeutics Discovery, Cleveland Clinic, Cleveland, OH, USA.
Berkley E GryderDepartment of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0003-0130-2302

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Mechanisms of Androgen Receptor Inverse Agonists in Advanced Prostate CancerR01CA291963 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Berkley E Gryder · 2024 to 2026
$2.8M
Functional Genomics Training Program (FGTP)T32GM135081 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI Thomas Louis LaFramboise, Helen C Miranda · 2020 to 2026
$1.3M
Epigenetic drivers of lung metastasis in osteosarcomaF30CA294663 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI CHIN, DIANA · 2024 to 2025
$109k
NCI NIH HHS F30 CA294663NCI NIH HHS P30 CA043703NCI NIH HHS R01 CA291963NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM135081
6 · The paper itself

Abstract

RNA Polymerase II (Pol2) organizes transcription through higher-ordered chromatin clusters that integrate promoter and enhancer interactions to coordinate gene expression. Nevertheless, the features that distinguish unique classes of Pol2-mediated clusters remain to be defined. Here, we identify two distinct classes of Pol2-mediated clusters: one enriched for CpG islands, promoter-promoter interactions, and housekeeping gene expression, and another characterized by high CBP/p300 occupancy, enhancer-promoter looping, and lineage-defining (LD) transcriptional programs. Acute inhibition of CBP/p300 catalytic activity leads to rapid loss of acetylation at enhancers and preferential downregulation of LD genes, resulting in impaired cellular proliferation and activation of apoptotic programs. Integrative machine learning modeling reveals that cluster strength, RNA half-life, and CpG island content as strong predictors of genes sensitive to CBP/p300 inhibition. Together, these findings clarify enhancer-addiction and vulnerability to CBP/p300 inhibition.

Indexed as

CBP/p300chromatinclustersCpG islandsenhancer-addictionhistone acetylationrhabdomyosarcomaRNA Polymerase II

Identifiers

PMID42146532
PMCPMC13174452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.